BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35190110)

  • 21. Treatment of impending tumor lysis with single-dose rasburicase.
    Lee AC; Li CH; So KT; Chan R
    Ann Pharmacother; 2003 Nov; 37(11):1614-7. PubMed ID: 14565793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect.
    Ignaszewski M; Kohlitz P
    Am J Emerg Med; 2017 Sep; 35(9):1384.e1-1384.e2. PubMed ID: 28587951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to prevent and manage tumor lysis syndrome.
    Held-Warmkessel J
    Nursing; 2010 Feb; 40(2):26-31; quiz 31-2. PubMed ID: 20083976
    [No Abstract]   [Full Text] [Related]  

  • 24. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tumor lysis syndrome: risk factors and treatment].
    Hörl WH
    Wien Klin Wochenschr; 2005 Jan; 117(1-2):7-17. PubMed ID: 15986584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute tumor lysis syndrome in a 7-month-old with hepatoblastoma.
    Bercovitz RS; Greffe BS; Hunger SP
    Curr Opin Pediatr; 2010 Feb; 22(1):113-6. PubMed ID: 19926992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing malignancy-associated hyperuricemia with rasburicase.
    Cheson BD; Dutcher BS
    J Support Oncol; 2005; 3(2):117-24. PubMed ID: 15796443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
    Eng S; Lee CS; Ahn S; Sharma A
    J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
    Baeksgaard L; Sørensen JB
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era.
    Toda Y; Ashizawa M; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Nagayama T; Umino K; Minakata D; Morita K; Yamamoto C; Hatano K; Sato K; Fujiwara SI; Ohmine K; Kanda Y
    Int J Hematol; 2024 Jun; 119(6):660-666. PubMed ID: 38575822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor lysis syndrome: risk factors, diagnosis, and management.
    Burns RA; Topoz I; Reynolds SL
    Pediatr Emerg Care; 2014 Aug; 30(8):571-6; quiz 577-9. PubMed ID: 25098804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
    Cammalleri L; Malaguarnera M
    Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
    Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Onco-nephrology: tumor lysis syndrome.
    Wilson FP; Berns JS
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1730-9. PubMed ID: 22879434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
    Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
    Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
    Alakel N; Middeke JM; Schetelig J; Bornhäuser M
    Onco Targets Ther; 2017; 10():597-605. PubMed ID: 28203093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tumor lysis syndrome].
    Hagino T
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):984-8. PubMed ID: 20567098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.